Illumina (ILMN) Stock Price & Analysis

ILMN$207.01-2.54 -1.21%
Medical - Diagnostics & ResearchLarge CapHigh Quality
Compare
Market cap$31.30BEnterprise value$35.23BRevenue (TTM)$4.54BMarket positionTop 25%

Score

57
Neutral
Value
43
Quality
82
Growth
47

AI Analysis

Snapshot

Illumina looks like a quality compounder first — Quality 82/100 and an overall 57/100. Under the hood: P/E 38.5, about 18% below its own multi-year median.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

43
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

47
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

82
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Illumina, Inc. (ILMN) last printed $207.01. Equity value is $31.30B. Trailing earnings multiple 34.97. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$2.4B$2.75B$3.33B$3.54B$3.24B$4.53B$4.58B$4.5B$4.37B$4.34B

About

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Illumina (ILMN) Stock Price & Analysis

ILMN price $207.01 -2.54 -1.21%

Ticker
ILMN
Price
$207.01
Change
-2.54 -1.21%
Market cap
$31.30B
P/E
34.97
Forward P/E
34.70
Dividend yield
0.00%
Beta
1.45
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Stocklytics score
57
Value
43
Quality
82
Growth
47

Stocklytics score rationale: value 43, quality 82, growth 47.

AI Score 55. Illumina, Inc. has a market cap of $35.63 billion and a high price-to-earnings ratio of approximately 40.07, indicating potential overvaluation

Insights · Forecast · Financials · Learn

Stocklytics home · Screener